We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PCSK9 Race Heats Up as Amgen Candidate Enters Phase III
PCSK9 Race Heats Up as Amgen Candidate Enters Phase III
Positive results from the first long-term trial of evolocumab, Amgen’s next-generation heart drug, are heating up the race to develop the emerging class of drugs known as PCSK9 inhibitors.